ReviewMedical cannabis and cannabinoids
Cannabidiol-Derived Cannabinoids: The Unregulated Designer Drug Market Following the 2018 Farm Bill.
Review in Medical cannabis and cannabinoids. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Comparative GC-MS and LC-MS/MS characterization of four 8-hydroxyhexahydrocannabinol stereoisomers and their TMS derivatives.Forensic toxicology · 2026Article
- Toxicity and health effects of delta-8, delta-9, and delta-10-tetrahydrocannabinol and unregulated cannabinoids in vaping products.Toxicology reports · 2026Review
- Correlates of Derived Cannabis Product Awareness, Knowledge, Use, and Use Intentions Among Young Adults.Health education & behavior : the official publication of the Society for Public Health Education · 2026Article
- Not what it seems: analytical validation and label accuracy of commercial CBD oils using HPTLC.Journal of cannabis research · 2026Article
- Prevalence of Cannabidiol (CBD) Use Among Patients Taking Medications with Known Drug-Drug Interactions: A Cross-Sectional Analysis.Journal of clinical medicine · 2025Article
- Characterising a New Cannabis Trend: Extensive Analysis of Semi-Synthetic Cannabinoid-Containing Seizures From Germany.Drug testing and analysis · 2025Article
- Identification of Three Novel Tetrahydrocannabinol Analogs in the European Market.Drug testing and analysis · 2025Article
- Genotoxic assessment of aPharmaceutical biology · 2025Article
- The resurgence of synthetic cannabinoid receptor agonists as adulterants in the Era of Cannabis legalization: Lessons from prior epidemics and clinical implications.Neuroscience and biobehavioral reviews · 2025Review
- Parent and caregiver perceptions of cannabidiol products may put children at risk for unintentional exposure.Frontiers in public health · 2025Observational
- Easy Availability of Marijuana and Other Cannabis-Derived Products: What is the Missouri Poison Center Seeing?Missouri medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Background: In this review, we summarize current scientific knowledge on psychoactive cannabinoids synthesized from cannabidiol (CBD) and sold in the semi-legal market established in response to the passage of the US Agriculture Improvement Act of 2018, commonly known as the 2018 Farm Bill. The discussion focuses on recent developments that suggest this unregulated market may be fertile ground for a potential health crisis. Summary: Current research into CBD-derived cannabinoids is mainly limited to Δ Key Messages: The CBD-derived cannabinoid market is growing internationally, and the market has diversified to include potent synthetic cannabinoids. The products sold on this unregulated market are under-researched despite growing availability and consumer interest. Ernest investigation of the pharmacology of these novel cannabinoids and the contents of CBD-derived cannabinoid products is critical for monitoring this potential source of another vaping-related epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.